Search

DeAngelis is acknowledged for her groundbreaking research in the field of neuro-oncology over her more than 30-year career.

… Friday, September 25, 2020 Memorial Sloan Kettering (MSK) is proud to announce that Physician-in-Chief and Chief Medical Officer Lisa M. DeAngelis, MD, is included on Avenue Magazine ’s The Power List 2020 . The list of more than 50 visionaries within the New York metropolitan area comprises leaders

MSK researchers moved cancer science ahead in 2015 with landmark discoveries that suggest new treatment strategies and shed light on how the disease progresses.

… Tuesday, December 29, 2015 Microscopic image of spherical cluster of cells, most of them pink cells with a smaller number of blue ones. Microscopic image of a spherical organoid of intestinal cells. Taken from the blog post "Manipulating a Single Gene Turns Colorectal Cancer Cells Back to Normal." See

Learn how MSK's expertise in metastatic breast cancer helped a mother celebrate a long-awaited milestone with her family.

… Friday, July 12, 2024 When Emma Mon learned the breast cancer she’d been diagnosed with as young mother had returned and spread to her lungs, she feared her time was running out. But that was six years ago, and since then, she’s been living her life with metastatic (or Stage 4) breast cancer . It has

New findings by researchers at MSK and their collaborators at the Icahn School of Medicine point to an opportunity to improve therapies that use small RNAs to silence disease-causing genes, potentially including those involved in cancer.

… Friday, December 20, 2024 In everyday life, when things turn out the opposite of what you expect, it’s usually cause for frustration. In science, it’s often the starting point for discovery. That’s what happened to a team of researchers from Memorial Sloan Kettering Cancer Center (MSK) and their collaborators

MSK investigators are leading research focused on understanding how hereditary DNA mutations affect cancer development and therapy, and how to best treat people who carry these inherited risks in their genes.

… Monday, June 5, 2023 Researchers from Memorial Sloan Kettering Cancer Center (MSK) revealed new findings about hereditary cancers and genetics at the recent 2023 American Society of Clinical Oncology (ASCO) annual meeting. Genetic mutations that are passed down through families cause a significant percentage

Patients with primary gastrointestinal stromal tumor, a type of tumor found in the stomach or small intestine, who received imatinib (Gleevec ®) after complete removal of their tumor were significantly less likely to have a recurrence of the cancer compared to those who did not receive imatinib.

… Thursday, April 12, 2007 Memorial Sloan Kettering Cancer Center’s Ronald DeMatteo, MD, served as the principal investigator of a large cooperative group trial that found patients with primary gastrointestinal stromal tumor, a type of tumor found in the stomach or small intestine, who received imatinib

Researchers have identified a set of genetic abnormalities in patients with acute myelogenous leukemia (AML) that doctors can use to more accurately predict patients’ prognoses and select treatments that are most likely to benefit them. The study, led by investigators at Memorial Sloan Kettering Cancer Center, will be published in the March 22 issue of the New England Journal of Medicine.

… Wednesday, March 14, 2012 Researchers have identified a set of genetic abnormalities in patients with acute myelogenous leukemia (AML) that doctors can use to more accurately predict patients’ prognoses and select treatments that are most likely to benefit them. The study, led by investigators at Memorial

Memorial Sloan Kettering Cancer Center (MSK) executives, including longtime board member David Koch, along with construction workers and physicians will all gather today for a “topping off” ceremony to mark completion of the steel construction phase of the David H. Koch Center for Cancer Care. The 750,000-square-foot, 23-story outpatient cancer center on East 74th Street and FDR Drive is made possible by a landmark gift of $150 million from Mr. Koch, the largest single gift in the history of the institution.

… Thursday, May 11, 2017 Memorial Sloan Kettering Cancer Center (MSK) executives, including longtime board member David Koch, along with construction workers and physicians will all gather today for a “topping off” ceremony to mark completion of the steel construction phase of the David H. Koch Center

There has been much recent excitement about immunotherapy and the use of genetically engineered chimeric antigen receptor (CAR) T cells. Historically, CAR T cell immunotherapy has aimed to boost the immune system by giving immune cells the information they need to better recognize tumor cells as foreign and attack them. New work led by Hans-Guido Wendel, MD, of Memorial Sloan Kettering Cancer Center (MSK), and collaborator Karin Tarte of the University of Rennes, France, illustrates an untapped potential of CAR T cells to act as targeted delivery vehicles that can function as “micro-pharmacies” for precise therapeutic delivery.

… Thursday, September 29, 2016 VIDEO | 00:49 CART Cells That Function as Micro-Pharmacies Dr. Hans Guido Wendel explains the untapped potential of CAR T cells to act as targeted delivery vehicles that can function as “micro-pharmacies” for precise therapeutic delivery. Video Details There has been much

MSK worked tirelessly to provide the COVID-19 vaccine to patients and employees.

… Thursday, April 1, 2021 Giving COVID-19 vaccines to MSK patients has been an urgent mission for the hospital this year. Knowing that patients are anxious about getting protected from the virus, which is especially devastating to people with cancer, the MSK COVID-19 Vaccine Care Team and countless other